Research map: Association of prior Angiotensin receptor-neprilysin inhibitor use with the initial eGFR dip after initiation of SGLT2 inhibitors in patients with chronic kidney disease

Back to the article

Papers in this map

  1. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy · Vlado Perkovic · 2019 · 6222 citations · Cited by this paper
  2. Attribute-based cross-classification reveals sex- and age-specific prognostic impact of anemia in ADPKD · 2026 · Related
  3. Dapagliflozin in Patients with Chronic Kidney Disease · Hiddo J.L. Heerspink · 2020 · 5532 citations · Cited by this paper
  4. Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018–2023) · 2026 · Related
  5. Diabetic Kidney Disease · Radica Z. Alicic · 2017 · 2909 citations · Cited by this paper
  6. Low-protein brown rice in CKD: dietary substitution or microbiome signal? · 2026 · Related
  7. Empagliflozin in Patients with Chronic Kidney Disease · The EMPA-KIDNEY Collaborative Group · 2022 · 2647 citations · Cited by this paper
  8. Season-adaptive blood pressure management in older adults with CKD: a practical review · 2026 · Related
  9. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study · Luis Miguel Ruilope · 2010 · 603 citations · Cited by this paper
  10. Relationships of high mean corpuscular volume, low total iron binding capacity and protein-energy wasting in patients on maintenance hemodialysis · 2026 · Related
  11. Vasoactive Potential of the B1Bradykinin Receptor in Normotension and Hypertension · Irena Duka · 2001 · 146 citations · Cited by this paper
  12. Clinical and functional evaluation of non-missense MYH9 variants in MYH9-related disease · 2026 · Related
  13. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF · Carly Adamson · 2022 · 138 citations · Cited by this paper
  14. Zinc deficiency and antihypertensive treatment intensity in patients initiating dialysis: a cross-sectional analysis from the Jikei hemodialysis and peritoneal dialysis study (JHPS) · 2026 · Related
  15. The kallikrein–kinin system in health and in diseases of the kidney · Masao Kakoki · 2009 · 108 citations · Cited by this paper
  16. Early glomerular capillary C4d is associated with poor graft function in kidney transplant recipients with preformed donor-specific antibodies · 2026 · Related
  17. Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition · Nicholas L. Cruden · 2004 · 79 citations · Cited by this paper
  18. Renal function and comprehensive frailty in community-dwelling older adults: cross-sectional and longitudinal analyses · 2026 · Related
  19. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study · Hiromi Rakugi · 2022 · 79 citations · Cited by this paper
  20. Peroxidasin expression patterns predict fibrosis and kidney function decline in IgA nephropathy · 2026 · Related
  21. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia · Violaine Griol‐Charhbili · 2005 · 78 citations · Cited by this paper
  22. B1 Bradykinin Receptors and Carboxypeptidase M Are Both Upregulated in the Aorta of Pigs after LPS Infusion · Elisabeth Schremmer-Danninger · 1998 · 68 citations · Cited by this paper
  23. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure · Finnian R. Mc Causland · 2022 · 53 citations · Cited by this paper
  24. Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy · Frank Spillmann · 2002 · 42 citations · Cited by this paper
  25. Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study · Yuto Saijo · 2023 · 33 citations · Cited by this paper
  26. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess · Haruomi Nishio · 2023 · 18 citations · Cited by this paper
  27. Assessment of SGLT2 inhibitors' safety and discontinuation causes in patients with advanced chronic kidney disease: insights from a real-world data analysis · Peggy Perrin · 2024 · 13 citations · Cited by this paper
  28. Glomerular Hypertrophy and Initial Dip in Estimated Glomerular Filtration Rate Following Dapagliflozin Administration · Akihiro Shimizu · 2024 · 7 citations · Cited by this paper
  29. Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database · Tomohiko Kanaoka · 2024 · 7 citations · Cited by this paper
  30. Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome · Md. Moshiur Rahman · 2025 · 5 citations · Cited by this paper
  31. Study on the Effects of Angiotensin Receptor/Neprilysin Inhibitors on Renal Haemodynamics in Healthy Dogs · Mio Ishizaka · 2024 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)